医渡科技 12 通讯 | 2025 年

Yidu Tech Events in December 2025

集团亮点

Business Update

宫如璟女士获聘荣任港城大数码医学研究院顾问委员会委员

Ms. Gong Rujing Appointed as the IDM Advisory Committee of City University of Hong Kong

在香港城市大学数码医学研究院周年大会上，医渡科技创始人、董事长宫如璟女士获聘为该研究院顾问委员会成员。作为公司创始人及战略掌舵者，宫如璟女士长期致力于推动 AI 与大数据技术在临床诊疗、科研创新与公共健康治理中的体系化应用，并持续通过国际交流推动行业合作。此次聘任代表了学界对医渡科技及宫如璟女士在 AI 医疗领域创新实践的高度认可。未来，她将作为连接产业实践与学术研究的重要桥梁，进一步推动产学研深度融合，迈向更高质量的发展阶段。

At the annual meeting of the Institute of Digital Medicine at City University of Hong Kong, Ms. Gong Rujing, Founder and Chairlady of Yidu Tech, was appointed as the Advisory Committee of IDM. As the founder and strategic leader of the company, Ms. Gong has long been committed to advancing the systematic application of AI and big data technologies across clinical practice, scientific research innovation, and public health governance. She has also continuously promoted international exchange and cross-sector collaboration to drive progress in the industry. This appointment reflects the strong recognition from the academic community of Yidu Tech's innovation practices and Ms. Gong's leadership in the AI healthcare sector. Looking ahead, Ms. Gong will serve as an important bridge between industry practice and academic

research, further fostering deeper integration across industry, academia, and research, and supporting the next stage of high-quality development.

医渡科技加入上合经贸平台卫生可持续发展工作委员会，徐济铭荣膺首届理事

Yidu Tech Joins Trade and Economics Multifunctional Platform for the SCO Countries; CEO Xu Jiming Elected as First-Term Council Member

上海合作组织国家多功能经贸平台（上合家园）卫生可持续发展工作委员会正式成立。医渡科技凭借其在国际数字健康领域的成功实践与系统化建设能力入选组织成员单位，医渡科技联合创始人、CEO 徐济铭当选为委员会第一届理事。此次“成员单位”与“首届理事”的双重身份认可，不仅是对医渡科技技术实力、行业贡献及管理层专业能力的高度肯定，也标志着医渡科技在参与国际多边卫生合作、推动全球健康可持续发展方面迈出关键一步。

The Working Committee on Health Sustainability under the Trade and Economics Multifunctional Platform for the Shanghai Cooperation Organization (SCO) Countries has been officially established. Leveraging its proven international digital health practices and strong capability in building systematic healthcare solutions, Yidu Tech

has been selected as a member organization of the Committee. Meanwhile, Mr. Xu Jiming, Co-founder and CEO of Yidu Tech, has been elected as a first-term council member of the Committee. This dual recognition as a member entity and a first-term council member is not only a high affirmation of Yidu Tech's technological strength, industrial contributions and the professional capabilities of its management team, but also marks a crucial step for Yidu Tech in participating in international multilateral health cooperation and advancing the sustainable development of global health.

医渡科技当选中国互联网协会智慧医疗工作委员会副主委单位

Yidu Tech Elected as Vice Chair Unit of the Smart Healthcare Working Committee of the Internet Society of China

中国互联网协会智慧医疗工作委员会完成换届，医渡科技当选为第三届委员会副主任委员单位，以新角色与产、学、研、医各界力量共推智慧医疗发展。

同时，在中国互联网协会智慧医疗工作委员会主办，互联网医疗健康产业联盟、WHO 数字健康合作中心承办的“医疗健康数智融合创新应用主题论坛”上，公司技术创新副总

裁、AI 架构师李林峰博士分享的“大数据+大模型双中台”解决方案，为医院驶入高质量发展快车道提供了可复制的创新路径，也是对“围绕发展新质生产力，推动科技创新和产业创新深度融合”号召的务实响应。

The Smart Healthcare Working Committee of the Internet Society of China has recently completed its leadership transition, with Yidu Tech elected as a Vice Chair Unit of the Committee's third term. In this new role, Yidu Tech will work alongside stakeholders from industry, academia, research, and clinical practice to jointly advance the development of smart healthcare.

At the "Digital and Intelligent Integration Innovation Forum for Healthcare Applications, "hosted by the Smart Healthcare Working Committee of the Internet Society of China and organized by the Internet Healthcare Industry Alliance and the WHO Digital Health Collaboration Center, Dr. Linfeng Li, Vice President of Technology Innovation and AI Architect at Yidu Tech, presented the company's "Dual Middleware-Platform Architecture for Big Data and Large Language Models." The solution offers a replicable innovation pathway to support hospitals in accelerating high-quality development, and represents a practical response to the national call to foster new-quality productive forces and deepen the integration of technological innovation with industrial transformation.

医渡科技受邀出席中国与国际发展论坛，分享跨国界数字健康合作新范式

Yidu Tech Invited to the China and International Development Forum to Share New Models for Cross-Border Digital Health Collaboration

在商务部国际贸易经济合作研究院与联合国开发计划署驻华代表处联合举办的第六届“中国与国际发展论坛”上，医渡科技联合创始人、CEO 徐济铭受邀出席，并在“应用场景与协同路径：数字南方中的医疗卫生发展合作”专题会议圆桌讨论中以核心发言嘉宾身份，与来自研究机构、世界卫生组织、国家卫健委、医疗机构等领域的代表同台论道，立足医渡科技海外数字健康实践，深度解析 AI 技术如何为全球南方医疗卫生体系升级降本增效、提质扩面，分享兼具创新性与可操作性的合作经验。

At the 6th China and International Development Forum, jointly organized by the Chinese Academy of International Trade and Economic Cooperation (CAITEC) under the Ministry of Commerce and the United Nations Development Programme (UNDP) China, Yidu Tech Co-founder and CEO Xu Jiming was invited to participate and

delivered a keynote contribution during the roundtable session themed "Application Scenarios and Collaborative Pathways: Health Development Cooperation in the Digital Global South." Joining representatives from research institutions, the World Health Organization, China's National Health Commission, and healthcare providers, Xu shared Yidu Tech's international digital health practices and offered in-depth insights into how AI technologies can help health systems across the Global South improve efficiency, expand access, and enhance quality. He also highlighted practical and scalable cooperation models that combine innovation with real-world implementation.

医渡科技用 AI 为非公医疗构筑竞争力“护城河”

Yidu Tech Builds a Competitive "Moat" for Private Healthcare Through AI

在 2025 中国社会办医新生态大会上，医渡科技联合创始人、CEO 徐济铭发表主题演讲，直指非公医疗的破局核心：将“数据+AI”从锦上添花的工具，升级为驱动医院高质量增长的核心引擎。他表示，当前非公医疗竞争已告别拼资源的“粗放竞赛”，迈入拼价

值、拼体验、拼可持续性的“深耕时代”，并提出三大解题方向：从学科建设、运营体系、资源共享三个维度，重塑核心竞争力。

At the 2025 China Private Healthcare New Ecosystem Conference, Yidu Tech Co-founder and CEO Xu Jiming delivered a keynote address, highlighting the core breakthrough for private healthcare providers: elevating "data + AI" from a value-added tool to a central engine driving high-quality hospital growth. Xu noted that competition in the private healthcare sector has moved beyond a resource-driven "extensive race" and entered a new phase focused on value creation, patient experience, and long-term sustainability. He outlined three strategic directions for strengthening core competitiveness — reshaping clinical disciplines, optimizing operational systems, and enabling resource sharing — offering a structured pathway for private hospitals to build resilient and differentiated capabilities in the digital era.

医渡科技出席泰州 AI+药物研发沙龙并分享临床智能化实践

Yidu Tech Shares AI-Driven Clinical Intelligence Practices at Taizhou AI + Drug R&D Salon

在泰州医药园区举办的“中国电信 AI+药物研发公共服务平台沙龙”中，医渡科技生命科学事业部商务总监朱莉受邀出席，并就 AI 驱动的临床试验创新与全流程数智化管理分享了公司的实践经验与技术成果。此次沙龙聚焦人工智能与药物研发的融合创新。朱莉在交流中阐述了医渡科技如何通过数据智能与平台化服务，助力医药企业提升临床试验效率、保障数据质量，推动临床研究数字化转型。医渡科技将持续以技术赋能医药研发创新，与产业各方携手共同促进生物医药行业的高质量发展。

At the "China Telecom AI + Drug R&D Public Service Platform Salon" held in the Taizhou Pharmaceutical Park, Zhu Li, Business Director of Yidu Tech's Life Sciences Division, was invited to participate and share the company's practical experience and technical achievements in AI-driven clinical trial innovation and end-to-end digitalized management. The salon focused on the integrated innovation of artificial intelligence and drug development. During the discussion, Zhu highlighted how Yidu Tech leverages data intelligence and platform-based services to help pharmaceutical companies improve clinical trial efficiency, ensure data quality, and accelerate the digital transformation of clinical research. Looking ahead, Yidu Tech will continue to empower pharmaceutical R&D innovation through technology, working closely with industry partners to jointly advance the high-quality development of the biopharmaceutical sector.

医渡科技与清华卫健学院共建实践基地：首期产出 11 项成果

Yidu Tech and Tsinghua University's Vanke School of Public Health Co-build Practice Base, Delivering 11 Initial Outcomes

2025 年暑期，12 名来自清华大学 9 个不同院系的博士生，走进了医渡科技的实践基地。在短短 6 周时间里，他们不仅完成了 11 项科研任务，更攻克了 2 项关键技术，输出了 4 项创新算法或方法。其中，参与优化的流感预测模型将误差降低了约 20%；参与研发的肝癌治疗方案智能体，也在临床测试中显著提升了诊疗效率。

这是清华大学万科公共卫生与健康学院与医渡科技共建博士生实践基地的首期成果。2025 年 12 月 18 日，双方再次聚首，围绕首期成果进行深度复盘，并对 2026 年暑期项目的深化实施达成了清晰的规划，标志着这一校企协同育人平台正迈向更系统、更深入的新阶段。

In the summer of 2025, twelve PhD students from nine different departments at Tsinghua University joined Yidu Tech's practice base. Over just six weeks, they completed 11 research projects, addressed two critical technical challenges, and developed four innovative algorithms or methodologies. Among the outcomes, the jointly optimized influenza prediction model reduced forecasting error by approximately 20%, while the AI agent developed for liver cancer treatment significantly improved clinical efficiency during testing.

These achievements mark the first-phase results of the PhD Practice Base jointly established by Tsinghua University's Vanke School of Public Health and Yidu Tech. On December 18, 2025, both parties reconvened for an in-depth review of the initial outcomes and aligned on a clear roadmap for expanding the summer 2026 program, signaling that this university–industry collaborative training platform is entering a more systematic and deeper stage of development.



业务进展

Business Progress

医渡科技签约河南省国家人工智能应用中试基地

Yidu Tech Signs Partnership Agreement with Henan National AI Application Pilot Base

医渡科技作为核心生态伙伴受邀出席河南省健康产业发展大会，并签约成为国家人工智能应用中试基地（医疗领域）的首批合作伙伴。该中试基地旨在为医疗人工智能产品提供从算法验证、临床评价到合规申报的全链条中试服务，加速创新成果产业化进程。

此前，医渡科技已深度参与北京中试基地建设。从服务首都到赋能中原，医渡科技以“国家医疗AI创新核心共建者”的身份，深度参与京豫两大国家级人工智能中试基地建设，在全国协同创新的棋盘上，再布下一枚战略性的“国家队”棋子。

Yidu Tech was invited to attend the Henan Province Health Industry Development Conference as a core ecosystem partner and officially signed on as one of the first collaborators of the National AI Application Pilot Base (Healthcare Sector). The pilot base is designed to provide end-to-end validation services for medical AI products — spanning algorithm verification, clinical evaluation, and regulatory submission — accelerating the industrialization of innovative technologies.

Previously, Yidu Tech played a key role in the development of the Beijing pilot base. From supporting the capital region to empowering Central China, Yidu Tech continues to advance national healthcare AI innovation as a core co-builder, contributing to both the Beijing and Henan national pilot bases. This marks another strategic milestone in the company's participation in China's coordinated national innovation framework.

医渡科技助力“北肿临床试验”小程序上线，CTMS 系统已赋能全国 60 多家医院

Yidu Tech Supports the Launch of the “PKUCH Clinical Trials” Mini Program, with Its CTMS Platform Now Empowering Over 60 Hospitals Nationwide

医渡科技与北京大学肿瘤医院联合打造的临床试验管理体系（CTMS）移动端——“北肿临床试验”小程序正式上线。该程序深度融合微信生态，为试验参与者提供便捷的试验动态查询、药品服务获取和安全加密的沟通渠道。同时，小程序也帮助临床研究协调员（CRC）打破办公场景限制，实现移动化高效工作。

与北肿的合作成果，是医渡科技 CTMS 系统价值的一个例证。该平台作为医渡科技在 2025 年服贸会上发布的重要创新成果，其可靠性、专业性与普适性已得到广泛认可，目前已成功应用于全国 60 多家知名医院，支撑着各类复杂临床试验的高效开展。

The mobile extension of the Clinical Trial Management System (CTMS) jointly developed by Yidu Tech and Beijing Cancer Hospital — the "PKUCH Clinical Trials" WeChat Mini Program — has officially launched. Deeply integrated with the WeChat ecosystem, the program provides trial participants with convenient access to study updates, medication services, and secure encrypted communication channels. At the same time, it enables Clinical Research Coordinators (CRC) to work more efficiently on the go, removing traditional office constraints.

The collaboration with Beijing Cancer Hospital represents a strong example of the value delivered by Yidu Tech's CTMS platform. First unveiled as a major innovation at the 2025 China International Fair for Trade in Services, the platform's reliability, professionalism, and broad applicability have since gained widespread recognition. To date, it has been successfully deployed across more than 60 leading hospitals nationwide, supporting the efficient execution of diverse and complex clinical trials.

医渡科技联袂清华长庚医院启动数字科技研发平台建设并发布心电大模型

Yidu Tech and Tsinghua Changgung Hospital Launch Digital Technology R&D Platform and Unveil ECG LLM

在清华大学临床医学科技创新大会上，北京清华长庚医院与医渡科技正式启动数字科技研发平台建设，该平台将成为北京清华长庚医院所构建的覆盖“临床研究—临床转化—药械研发—数据科学—医工结合—临床验证”的全链条协同创新体系的关键一环。北京清华长庚医院副院长张萍教授，北京清华长庚医院执行长柳玉倩女士与医渡科技联合创始人、CEO 徐济铭先生，医渡科技技术创新副总裁李林峰博士出席了启动仪式。在大会的创新成果发布环节，徐济铭先生还作为企业代表参与“清心”心电大模型发布。

当前，以人工智能为代表的数字科技正成为驱动医疗健康产业变革的核心引擎。此次合作是双方响应“健康中国 2030”战略号召，推动临床医学与数字技术深度协同的重要实践。

At the Clinical Medicine Science and Technology Innovation Conference of Tsinghua University, Beijing Tsinghua Changgung Hospital and Yidu Tech officially launched the construction of a Digital Technology R&D Platform. The platform will serve as a key component of the hospital's end-to-end collaborative innovation system, spanning clinical research, clinical translation, medical device and drug development, data science, medical–engineering integration, and clinical validation. Professor Zhang Ping, Vice President of Beijing Tsinghua Changgung Hospital; Liu Yuqi, Chief Executive Officer of the hospital; Xu Jiming, Co-founder and CEO of Yidu Tech; and Li Linfeng, Vice President of Technology Innovation at Yidu Tech, attended the launch ceremony. During the conference's innovation showcase session, Xu also participated as a corporate representative in the release of the "Qingxin" ECG LLM.

Today, digital technologies led by artificial intelligence are becoming a core engine driving transformation across the healthcare industry. This collaboration represents an important step by both parties in response to the Healthy China 2030 strategy, advancing the deep integration of clinical medicine and digital technologies.

医渡科技与深信服达成战略合作，携手共建新一代安全高效 AI 科研数据平台

Yidu Tech and Sangfor Form Strategic Partnership to Co-build a New-Generation Secure and High-Efficiency AI Research Data Platform

双方围绕医院科研数据管理与研究的核心需求，在保障信息安全前提下，共同打造“高效协同、弹性扩展、安全可靠”的新一代 AI 科研数据平台。该平台不仅为医院提供了从数据整合、算力调度到全流程科研协作的一体化解决方案，也推动了医疗科研模式的转型升级——从分散走向集约、从低效走向敏捷、从孤立走向协同。未来，双方将持续深化合作，共同构建智慧医疗科研新生态，推动我国医疗行业科研创新能力实现整体跃升，为健康中国建设贡献科技力量。

Yidu Tech and Sangfor have entered into a strategic partnership to jointly develop a next-generation AI research data platform designed to be efficient, scalable, and secure. Centered on the core needs of hospital research data management and scientific collaboration, the platform ensures robust information security while enabling high-efficiency coordination and elastic expansion. The platform delivers an integrated

solution spanning data integration, computing resource orchestration, and end-to-end research collaboration. It also supports the transformation of medical research models — shifting from fragmentation to consolidation, from low efficiency to agility, and from isolated workflows to collaborative ecosystems. Looking ahead, the two parties will continue to deepen their partnership to jointly build a new smart healthcare research ecosystem, advancing the overall innovation capacity of China's medical research sector and contributing technological momentum to the Healthy China initiative.

医渡科技签约市级全民健康信息平台

Yidu Tech Signs Agreement for Municipal Population Health Information Platform

此次签约项目实现了对全市二级及以上医院及全部区县健康医疗数据的汇聚，将通过系统化数据治理，有效支撑三医联动可视化、居民端健康记录、区域临床研究、医生端健康记录跨院查询等重点应用落地。该项目将助力全市提升三医联动信息化水平，实现

“惠民、助医、促研、辅政”的多维目标。同时，也为全市人工智能基地建设提供关键基础支撑。签约金额达 2280 万元。

Yidu Tech has signed an agreement for the development of a municipal population health information platform. The project will integrate health and medical data from all secondary-level and above hospitals across the city, as well as from all districts and counties. Through systematic data governance, the platform will support the implementation of key applications including visualized coordination across healthcare services, medical insurance and pharmaceuticals, resident-facing health records, regional clinical research, and cross-hospital access to physician health records. The initiative will help enhance the city's digital capabilities for integrated healthcare governance, advancing multidimensional objectives of improving public services, supporting clinicians, enabling research, and strengthening policymaking. It will also provide critical foundational support for the city's AI innovation base. The total contract value of the project is RMB 22.8 million.

医渡科技中标国家消化系统疾病临床医学研究中心江苏省分中心多中心数据平台项目

Yidu Tech Wins Bid for Multi-Center Data Platform Project of the Jiangsu Sub-Center of the National Clinical Research Center for Digestive Diseases

无锡消化系统疾病多中心项目是以无锡市某三甲医院牵头，覆盖无锡全市的主要医院。该项目的成功中标，标志着公司在多中心领域又拿下一个重要关键项目，不仅有助于全面拓展公司在无锡地区的市场影响力，也进一步深化了公司与无锡市该三甲医院的战略合作关系，是双方合作进程中又一重要里程碑。中标金额近 800 万元。

Yidu Tech has successfully secured the multi-center data platform project for the Jiangsu Sub-Center of the National Clinical Research Center for Digestive Diseases.

Led by a Class A tertiary hospital in Wuxi, the project brings together major hospitals across the city to support collaborative research on digestive diseases. The successful bid marks another key milestone in Yidu Tech's expansion within the multi-center clinical research domain. It not only strengthens the company's market presence in Wuxi, but also further deepens its strategic partnership with the leading tertiary hospital. This achievement represents an important step forward in the ongoing collaboration between both parties. The contract value is approximately RMB 8 million.

医渡科技中标天津市某三甲医院智能临床研究一体化平台建设项目

Yidu Tech Wins Bid for Intelligent Integrated Clinical Research Platform Project at a Tertiary Hospital in Tianjin

本项目致力于构建新一代智能临床试验研究平台，以“数据驱动、智能协同”为核心理念，通过四大系统的深度集成，实现临床试验全流程的数字化管理。平台旨在显著提升临床研究效率与数据质量，确保全程合规可溯源，同时赋能研究团队、优化患者体验，力争打造肿瘤专科领域临床研究的智能化范例。中标金额超 700 万元。

Yidu Tech has secured the project to build an intelligent integrated clinical research platform for a Class A tertiary hospital in Tianjin. The initiative focuses on developing a next-generation smart clinical trial research platform, guided by the core principles of "data-driven intelligence and collaborative workflows." Through deep integration of four core systems, the platform will enable end-to-end digital management of clinical trials. The platform is designed to significantly enhance research efficiency and data quality, ensure full compliance and traceability across the entire process, and empower research teams while improving patient experience. The project aims to establish a benchmark for intelligent clinical research in the oncology specialty. The contract value exceeds RMB 7 million.

医渡科技中标吉林市某三甲医院临床研究 EDC 系统

Yidu Tech Wins Bid for Clinical Research EDC System at a Tertiary Hospital in Jilin

中标吉林市某三甲医院临床研究 EDC 系统项目，标志着医渡科技在该医院的业务拓展再获重要进展。在此次竞争激烈的招投标中，医院继续选择与医渡科技合作，体现了对公司技术实力与服务体系的充分认可。此次合作为未来双方在更多业务领域的深化协作奠定了坚实基础。

Yidu Tech has successfully secured the clinical research EDC system project for a Class A tertiary hospital in Jilin, marking another important milestone in the company's business expansion with the hospital. Amid a highly competitive bidding process, the hospital once again selected Yidu Tech as its partner, reflecting strong confidence in the company's technical capabilities and service framework. This collaboration further strengthens the partnership between both parties and lays a solid foundation for deeper cooperation across additional clinical research and digital healthcare initiatives in the future.

集团荣誉

Honors of Yidu Tech

医渡科技荣膺多项大奖并连续三年获行业重磅白皮书收录

Yidu Tech Recognized with Multiple Industry Awards and Featured for Three Consecutive Years in Leading Digital Health White Paper

动脉智库发布的《2025 数字医疗年度创新白皮书》中指出，医疗人工智能为 2025 数字医疗行业高价值领域。医渡科技作为长期专注于医疗人工智能融合创新的企业，其持续性的实践与突破，成为观察产业演进的一个关键样本，公司在 AI 医疗领域的创新实践已连续第三年被该白皮书收录。

此外，医渡科技近期相继荣获“2025 年度科技普惠医疗创新成果奖”、入选“中国医疗数字化企业 TOP20”，并被评为“最具价值人工智能公司”。白皮书收录与行业大奖的多重肯定，既是对医渡科技技术创新实力、场景落地能力以及行业价值创造的认可，也印证了其在行业内持久而广泛的影响力。

According to the 2025 Digital Health Annual Innovation White Paper released by VBData, medical artificial intelligence has been identified as a high-value segment within the digital health industry in 2025. As a company long dedicated to advancing the integration of AI and healthcare, Yidu Tech's sustained innovation and practical breakthroughs have become a key reference point for observing industry evolution. The company's AI healthcare practices have now been featured in the white paper for the third consecutive year.

In addition, Yidu Tech has recently received multiple industry recognitions, including the "2025 Technology for Inclusive Healthcare Innovation Award", selection among the "Top 20 Digital Healthcare Companies in China", and recognition as one of the "Most Valuable Artificial Intelligence Companies". These acknowledgements from both industry reports and award institutions reflect strong validation of Yidu Tech's technological innovation, real-world implementation capabilities, and value creation across healthcare scenarios — underscoring the company's enduring and broad-based impact within the sector.

医渡科技“医生 Copilot”项目获评 2025 全国企业数字中国建设优秀应用案例

Yidu Tech's "Doctor Copilot" Project Recognized as a 2025 National Outstanding Digital China Application Case

医渡科技“医生 Copilot”赋能医院项目，成功入选“2025 全国企业数字中国建设优秀应用案例”，并获颁荣誉证书。该项目以人工智能技术为核心，构建了 AI 驱动的新一代智能诊疗模式。通过“医生 Copilot”系统的应用，在提升临床诊疗效率、辅助医生决策、优化患者服务流程等方面展现了显著成效，是人工智能技术在医疗领域落地实践的重要探索，此次获奖体现了行业对医渡科技在医疗人工智能领域技术创新与应用成果的认可。

Yidu Tech's "Doctor Copilot" hospital empowerment project has been selected as a 2025 National Outstanding Application Case for Digital China Enterprise Development and awarded an official certificate of recognition. Centered on artificial intelligence, the project has established a next-generation, AI-driven intelligent care model. Through the deployment of the Doctor Copilot system, the project has demonstrated significant impact in improving clinical efficiency, supporting physician decision-making, and optimizing patient service workflows. It represents an important practical exploration of AI implementation in healthcare. This recognition reflects industry acknowledgment of Yidu Tech's technological innovation and application achievements in medical artificial intelligence.


编号：2025SZ40

荣誉证书

HONORARY CREDENTIAL

2025全国企业数字中国建设优秀应用案例

申报单位：医渡科技

案例名称：医渡科技“医生Copilot”赋能中山大学肿瘤防治中心：构建AI驱动的新一代智能诊疗范式

德本咨询
互联网周刊
eNet研究院
2025年12月

医渡科技“健康画像”落地潍坊，连夺双冠

Yidu Tech's "Health Profiling" Project Launched in Weifang Wins Two Major Innovation Awards

医渡科技与山东省潍坊市卫生健康委员会联合申报的“健康画像”和“潍坊市全民健康数字画像”项目，凭借其前瞻性的服务模式与显著的惠民成效，成功斩获 2025 年山东省“互联网+医疗健康”创新应用案例“惠民服务实践一等奖”及 2025 年首届“齐鲁数智医疗健康”创新大赛“服务创新一等奖”。该项目不仅在理念上具有前瞻性，更在落地实践中取得显著成效，成为区域医疗健康数字化转型的典范。

The "Health Profiling" and "Weifang City Population Health Digital Profiling" projects jointly submitted by Yidu Tech and the Weifang Municipal Health Commission of Shandong Province have received two top honors in 2025, in recognition of their forward-looking service model and tangible public-health impact. The projects were awarded "First Prize for Public Service Practice" in Shandong Province's "Internet + Healthcare" Innovation Application Cases, as well as "First Prize for Service Innovation" at the inaugural Qilu Digital Healthcare Innovation Competition. Beyond their conceptual innovation, the projects have delivered measurable results in real-world implementation, establishing a benchmark for regional digital transformation in healthcare.

附件

2025 年山东省“互联网+医疗健康”创新应用案例获奖名单

一等奖（9 项）

案例方向	案例名称	申报单位	联合申报单位
惠民服务实践（2 项）	互联网医院+家庭医生系统建设	山东省妇幼保健院	
	健康画像	潍坊市卫生健康委员会	中国移动通信集团山东有限公司 医渡云(北京)技术有限公司

附件

2025 年“齐鲁数智医疗健康”创新大赛获奖名单

一等奖（10 项）

赛道	项目名称	牵头单位	联合申报单位
服务创新（2 项）	潍坊市全民健康数字画像	潍坊市卫生健康委员会	中国移动通信集团山东有限公司 医渡云(北京)技术有限公司
	基于大模型的基层高血压“筛-诊-治-管”平台建设	山东省计算中心(国家超级计算济南中心)	临沭县人民医院 山东华数信息技术股份有限公司 山东山科智心科技有限公司

政策利好

Policy Benefits

商保创新药目录发布，科技平台成政策落地关键赋能者

China Releases Its First Commercial Insurance Innovative Drug Catalogue, with Technology Platforms Emerging as Key Enablers of Policy Implementation

12 月 7 日，国家医保局正式发布我国首版商保创新药目录，纳入 19 种药品，涵盖百万元级 CAR-T 抗癌药、阿尔茨海默症新药、儿童罕见病特效药等临床价值大、创新程度高的药品，目录将于 2026 年 1 月 1 日起正式实施。这一创新药支付制度不仅为患者带来用药可及性的重大提升，更推动商业健康险与创新药产业的深度融合。医渡科技凭借 AI 医疗能力，已中标国家医保局相关课题，并为多省市“惠民保”提供精算定价、风控运营等全流程服务，其担任主运营的“深圳惠民保”已率先将目录内药品全部纳入保障。政策落地有望进一步发挥公司技术优势，一方面赋能保险公司设计并管理可持续的创新保险产品，另一方面助力药企实现创新价值的市场转化。

On December 7, China's National Healthcare Security Administration officially released the country's first Commercial Insurance Innovative Drug Catalogue, covering 19 medicines including high-cost CAR-T cancer therapies, new treatments for Alzheimer's disease, and breakthrough drugs for rare pediatric conditions. The catalogue will come into effect on January 1, 2026. This innovative drug payment mechanism not only significantly improves patient access to medications, but also promotes deeper integration between commercial health insurance and the innovative pharmaceutical sector. Leveraging its AI healthcare capabilities, Yidu Tech has secured related research projects commissioned by the National Healthcare Security Administration and provides end-to-end services — including actuarial pricing and risk management operations — for multiple provincial and municipal "Hui Min Bao" programs. Notably, Shenzhen Hui Min Bao, for which Yidu Tech serves as the lead

operator, has already become the first program to fully include all catalogue-listed drugs in its coverage.

As the policy is implemented nationwide, Yidu Tech's technology platform is expected to further amplify its role across the ecosystem — enabling insurers to design and manage sustainable innovative insurance products, while helping pharmaceutical companies translate scientific innovation into real-world market value.

投资者交流

Investor Communication

医渡科技圆满举办三地投资者交流会，详解 FY26 中期业绩与双中台战略进展

Yidu Tech Successfully Hosts Investor Meetings Across Three Cities, Sharing FY26 Interim Results and Progress of Dual Middleware Platform Strategy

医渡科技圆满完成了在三个核心城市（北京、香港、上海）举行的“FY26 中期业绩投资者交流系列活动”。公司执行董事兼首席财务官封晓瑛女士与投资者关系总监王晓炜女士与各地投资者就公司中期业绩表现、战略推进成效以及医疗智能领域的深度布局进行了充分沟通。期间，管理层系统介绍了公司“数据中台+AI 中台”双引擎战略的落地成果，着重展示了基于大模型基础设施与 AI 工具平台如何有效降低技术应用门槛，加速在医药险等多个业务场景中的价值实现。通过系列交流，投资者对公司“技术驱动产业”的发展路径有了更清晰的认识，进一步巩固了资本市场对公司长期成长潜力的信心。

Yidu Tech successfully completed its "FY26 Interim Results Investor Meeting Series" held across three core cities — Beijing, Hong Kong, and Shanghai. Ms. Feng Xiaoying, Executive Director and CFO, together with Ms. Wang Xiaowei, Director of Investor Relations, engaged in in-depth discussions with investors in each location on the company's interim performance, progress in strategic execution, and its comprehensive deployment in medical intelligence. During the sessions, management

systematically introduced the implementation progress of the company's "Data Middleware Platform + AI Middleware Platform" dual-engine strategy, with a focus on demonstrating how large language model infrastructure and AI tool platforms effectively lower barriers to technology adoption and accelerate value realization across multiple business scenarios, including pharmaceuticals and insurance. Through the series of exchanges, investors gained a clearer understanding of the company's "technology-driven industry" development path, further strengthening capital market confidence in Yidu Tech's long-term growth potential.

医渡科技月内 11 次回购耗资超 1740 万港元，持续强化市场信心

Yidu Tech Conducts 11 Share Buybacks in a Single Month, Investing Over HKD 17.4 Million to Reinforce Market Confidence

12 月期间，医渡科技在港股市场累计开展 11 次股份回购，共回购约 344 万股，涉及总金额超过 1740 万港元。这一系列回购行动持续向市场传递出管理层对公司内在价值与发展前景的坚定信心，展现了公司稳健的财务状况与长期发展的决心，有助于进一步稳定投资者预期、夯实市场信任基础。

During December, Yidu Tech carried out a total of 11 share buybacks on the Hong Kong stock market, repurchasing approximately 3.44 million shares with an aggregate amount exceeding HKD 17.4 million. This series of buyback actions continues to convey management's strong confidence in the company's intrinsic value and development prospects, demonstrating its sound financial position and long-term commitment to growth. The initiative also helps further stabilize investor expectations and strengthen market trust.